Curis Inc. (NASDAQ:CRIS) – Analysts at FBR & Co upped their Q3 2016 earnings estimates for Curis in a research report issued on Monday. FBR & Co analyst C. James now anticipates that the firm will post earnings of ($0.09) per share for the quarter, up from their prior estimate of ($0.13). FBR & Co currently has a “Buy” rating on the stock. FBR & Co also issued estimates for Curis’ FY2016 earnings at ($0.34) EPS, FY2017 earnings at ($0.51) EPS, FY2018 earnings at ($0.61) EPS, FY2019 earnings at ($0.43) EPS and FY2020 earnings at ($0.21) EPS.

A number of other brokerages have also commented on CRIS. Zacks Investment Research upgraded Curis from a “sell” rating to a “hold” rating in a report on Tuesday, October 4th. RBC Capital Markets set a $7.00 price target on Curis and gave the stock a “buy” rating in a report on Wednesday, October 12th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $7.00 price target on shares of Curis in a report on Wednesday, September 7th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $5.05.

Earnings History and Estimates for Curis (NASDAQ:CRIS)

Shares of Curis (NASDAQ:CRIS) traded up 1.259% during mid-day trading on Wednesday, hitting $2.815. The company had a trading volume of 130,020 shares. Curis has a one year low of $1.25 and a one year high of $3.42. The company’s 50-day moving average is $2.38 and its 200 day moving average is $1.91. The company’s market capitalization is $364.46 million.

Curis (NASDAQ:CRIS) last released its earnings results on Thursday, August 4th. The company reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09). The firm earned $1.70 million during the quarter, compared to the consensus estimate of $2.05 million. Curis had a negative return on equity of 65.51% and a negative net margin of 526.72%. The company’s revenue was down 19.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.06) EPS.

In other news, major shareholder Discovery Technologie Aurigene bought 10,208,333 shares of the firm’s stock in a transaction on Wednesday, September 7th. The stock was acquired at an average cost of $2.40 per share, with a total value of $24,499,999.20. Following the completion of the transaction, the insider now directly owns 27,328,464 shares of the company’s stock, valued at approximately $65,588,313.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.09% of the stock is owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Curis by 2.5% in the first quarter. Geode Capital Management LLC now owns 772,054 shares of the company’s stock valued at $1,243,000 after buying an additional 18,476 shares during the period. Janney Montgomery Scott LLC bought a new position in shares of Curis during the second quarter valued at $359,000. Bank of New York Mellon Corp boosted its position in shares of Curis by 0.7% in the second quarter. Bank of New York Mellon Corp now owns 357,246 shares of the company’s stock valued at $558,000 after buying an additional 2,501 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in shares of Curis during the first quarter valued at $248,000. Finally, State Street Corp boosted its position in shares of Curis by 8.7% in the second quarter. State Street Corp now owns 1,579,103 shares of the company’s stock valued at $2,464,000 after buying an additional 126,694 shares during the period. Institutional investors own 52.36% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

5 Day Chart for NASDAQ:CRIS

Receive News & Stock Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related stocks with our FREE daily email newsletter.